Aquestive Therapeutics (AQST) Capital Expenditures (2017 - 2026)

Aquestive Therapeutics' Capital Expenditures history runs 10 years deep, the most recent figure standing at $52000.0 for Q1 2026.

• On a quarterly basis, Capital Expenditures fell 61.48% year-over-year to $52000.0 in Q1 2026; TTM through Mar 2026 was -$31000.0, a 111.7% decrease from a year earlier, with the FY2025 full-year figure at $52000.0, down 67.3% from the prior year.
• Capital Expenditures advanced to $52000.0 in Q1 2026 per AQST's latest filing, from -$425000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $826000.0 in Q2 2023 and bottomed at -$979000.0 in Q4 2023.
• The 5-year median for Capital Expenditures is $78000.0 (2022), against an average of $80437.5.
• Across the five-year window, Capital Expenditures sank 3865.38% in 2023 and soared 1350.0% in 2024, its largest moves.
• Year by year, Capital Expenditures stood at $26000.0 in 2022, then sank by 3865.38% to -$979000.0 in 2023, then surged by 116.24% to $159000.0 in 2024, then sank by 367.3% to -$425000.0 in 2025, then jumped by 112.24% to $52000.0 in 2026.
• Per Business Quant, the three latest AQST Capital Expenditures figures stand at $52000.0 (Q1 2026), -$425000.0 (Q4 2025), and $394000.0 (Q3 2025).